Characteristics of HSCT
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| Age at transplant, mean (SD), y | 5.84 (6.11) | 4.08 (4.03) | 8.79 (7.75) | .002 |
| Donor relative, n (%) | ||||
| Aunt/uncle | 4 (6.2) | 2 (5.0) | 2 (8.3) | .007 |
| Parent | 52 (81.2) | 37 (92.5) | 15 (62.5) | |
| Sibling | 6 (9.4) | 0 (0.0) | 6 (25.0) | |
| Unknown | 2 (3.1) | 1 (2.5) | 1 (4.2) | |
| HLA match, n (%) | ||||
| 3/6 or 4/8 or 5/10 | 47 (73) | 32 (80) | 15 (61) | .003 |
| 6/10 or 7/10 | 13 (21) | 4 (9) | 9 (37) | |
| 7/8 or 8/10 | 2 (3) | 2 (5) | 0 (0) | |
| Unknown | 2 (3.1) | 2 (5.0) | 0 (0.0) | |
| Donor age, mean (SD), y | 34.79 (9.06) | 35.79 (5.92) | 33.12 (12.67) | .256 |
| CMV status D/R, n (%) | ||||
| –/– | 7 (10.9) | 5 (12.5) | 2 (8.3) | .660 |
| +/− | 14 (21.9) | 10 (25.0) | 4 (16.7) | |
| +/+ | 39 (60.9) | 22 (55.0) | 17 (70.8) | |
| +/uk | 4 (6.2) | 3 (7.5) | 1 (4.2) | |
| Source of stem cells, n (%) | ||||
| BM | 12 (18.8) | 0 (0.0) | 12 (50.0) | <.001 |
| PB | 51 (79.7) | 40 (100.0) | 11 (45.8) | |
| BM + PB | 1 (1.6) | 0 (0.0) | 1 (4.2) | |
| Chemotherapy-based regimen, n (%) | ||||
| Bu | 24 (37.5) | 8 (20.0) | 16 (66.7) | <.001 |
| Treo | 34 (53.1) | 32 (80.0) | 2 (8.3) | |
| Other | 6 (9.4) | 0 (0.0) | 6 (25.0) | |
| Serotherapy, n (%) | .019 | |||
| Alemtuzumab | 11 (17.2) | 3 (7.5) | 8 (33.3) | |
| ATG | 21 (32.8) | 13 (32.5) | 8 (33.3) | |
| ALG | 26 (40.6) | 21 (52.5) | 5 (20.8) | |
| No serotherapy | 6 (9.4) | 3 (7.5) | 3 (12.5) | |
| GVHD prophylaxis, n (%) | ||||
| None | 30 (46.9) | 30 (75.0) | 0 (0.0) | <.001 |
| Monotherapy | 10 (15.6) | 9 (22.5) | 1 (4.2) | |
| Bitherapy | 23 (35.9) | 1 (2.5) | 22 (91.7) | |
| Tritherapy | 1 (1.6) | 0 (0.0) | 1 (4.2) |
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| Age at transplant, mean (SD), y | 5.84 (6.11) | 4.08 (4.03) | 8.79 (7.75) | .002 |
| Donor relative, n (%) | ||||
| Aunt/uncle | 4 (6.2) | 2 (5.0) | 2 (8.3) | .007 |
| Parent | 52 (81.2) | 37 (92.5) | 15 (62.5) | |
| Sibling | 6 (9.4) | 0 (0.0) | 6 (25.0) | |
| Unknown | 2 (3.1) | 1 (2.5) | 1 (4.2) | |
| HLA match, n (%) | ||||
| 3/6 or 4/8 or 5/10 | 47 (73) | 32 (80) | 15 (61) | .003 |
| 6/10 or 7/10 | 13 (21) | 4 (9) | 9 (37) | |
| 7/8 or 8/10 | 2 (3) | 2 (5) | 0 (0) | |
| Unknown | 2 (3.1) | 2 (5.0) | 0 (0.0) | |
| Donor age, mean (SD), y | 34.79 (9.06) | 35.79 (5.92) | 33.12 (12.67) | .256 |
| CMV status D/R, n (%) | ||||
| –/– | 7 (10.9) | 5 (12.5) | 2 (8.3) | .660 |
| +/− | 14 (21.9) | 10 (25.0) | 4 (16.7) | |
| +/+ | 39 (60.9) | 22 (55.0) | 17 (70.8) | |
| +/uk | 4 (6.2) | 3 (7.5) | 1 (4.2) | |
| Source of stem cells, n (%) | ||||
| BM | 12 (18.8) | 0 (0.0) | 12 (50.0) | <.001 |
| PB | 51 (79.7) | 40 (100.0) | 11 (45.8) | |
| BM + PB | 1 (1.6) | 0 (0.0) | 1 (4.2) | |
| Chemotherapy-based regimen, n (%) | ||||
| Bu | 24 (37.5) | 8 (20.0) | 16 (66.7) | <.001 |
| Treo | 34 (53.1) | 32 (80.0) | 2 (8.3) | |
| Other | 6 (9.4) | 0 (0.0) | 6 (25.0) | |
| Serotherapy, n (%) | .019 | |||
| Alemtuzumab | 11 (17.2) | 3 (7.5) | 8 (33.3) | |
| ATG | 21 (32.8) | 13 (32.5) | 8 (33.3) | |
| ALG | 26 (40.6) | 21 (52.5) | 5 (20.8) | |
| No serotherapy | 6 (9.4) | 3 (7.5) | 3 (12.5) | |
| GVHD prophylaxis, n (%) | ||||
| None | 30 (46.9) | 30 (75.0) | 0 (0.0) | <.001 |
| Monotherapy | 10 (15.6) | 9 (22.5) | 1 (4.2) | |
| Bitherapy | 23 (35.9) | 1 (2.5) | 22 (91.7) | |
| Tritherapy | 1 (1.6) | 0 (0.0) | 1 (4.2) |
ALG, rabbit antilymphocyte globulin; BM, bone marrow; CMV, cytomegalovirus; D/R, donor/receiver; PB, peripheral blood; Treo, treosulfan; uk, unknown.
Boldface P values are statistically significant (P < .05).